 Connection
Elaine Lam to Melanoma
This is a "connection" page, showing publications Elaine Lam has written about Melanoma.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.213 |
|
|
|
-
Gouda MA, Voss MH, Tawbi H, Gordon M, Tykodi SS, Lam ET, Vaishampayan U, Tannir NM, Chaves J, Nikolinakos P, Fan A, Lee R, McDermott D, Shapiro GI, Gandhi L, Bhatia S, Katragadda V, Meric-Bernstam F. A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer. ESMO Open. 2025 May; 10(5):104536.
Score: 0.146
-
Monk P, Lam E, Mortazavi A, Kendra K, Lesinski GB, Mace TA, Geyer S, Carson WE, Tahiri S, Bhinder A, Clinton SK, Olencki T. A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma. J Immunother. 2014 Apr; 37(3):180-6.
Score: 0.067
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|